An Observer-blind Study to Assess the Safety, Reactogenicity and Immunogenicity of Different Formulations of GSK Biologicals' Investigational RSV Vaccine (GSK3003891A), in Healthy Women

Trial Profile

An Observer-blind Study to Assess the Safety, Reactogenicity and Immunogenicity of Different Formulations of GSK Biologicals' Investigational RSV Vaccine (GSK3003891A), in Healthy Women

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Aug 2017

At a glance

  • Drugs GSK 3003891A (Primary) ; DTaP vaccine
  • Indications Respiratory syncytial virus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Acronyms RSV F-020
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 28 Jul 2016 Status changed from active, no longer recruiting to completed.
    • 15 Jul 2016 The trial was completed in Germany.
    • 01 Jun 2016 The trial was completed in Czech Republic.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top